IGFBP7 and acute kidney injury: The combination of TIMP-2 and IGFBP7 for the prediction of AKI in high risk patients has been examined in several landmark studies (Table 1) (26, 28, 45), and is now approved by the U.S. Food and Drug Administration for critically ill adults with one or more risk factors for AKI, including sepsis (25).